Bone Health of Women with CF Across the Age Spectrum

Why It Matters

Understanding how contraceptive choices affect bone density helps clinicians prevent early osteoporosis in women with cystic fibrosis, improving long‑term health outcomes.

Key Takeaways

• Women with CF face early osteoporosis due to slowed bone accrual
• Progesterone-only contraception linked to higher bone disease hazard in univariable analysis
• Multivariable model shows age and low BMI remain significant risk factors
• Systemic progesterone injections trend toward increased bone loss, not statistically significant
• Study limited by self-reported contraceptive histories and frequent method changes

Summary

At the 2025 North American Cystic Fibrosis Conference, pediatric endocrinologist Melinda Woo presented findings on bone health among women with cystic fibrosis, emphasizing how contraceptive choices may influence osteoporosis risk. The study, part of the CASE for CF project, surveyed 551 women across ten sites and linked self‑reported contraceptive use to longitudinal registry data spanning 13 years.

Women with CF accrue bone mass more slowly than peers, and risk factors such as increasing age, low body‑mass index and reduced lung function were confirmed. Univariable Cox models identified progesterone‑only methods, especially systemic injections, as associated with a higher hazard of developing bone disease, though multivariable analysis retained only age and BMI as independent predictors.

The investigators reported an 81 % concordance between registry‑reported osteopenia/osteoporosis and DEXA‑derived low bone density, lending credibility to the data. While systemic progesterone showed a non‑significant trend toward greater bone loss, frequent switching of contraceptive methods and reliance on retrospective self‑report limited statistical power.

These results suggest clinicians should weigh bone health when prescribing contraception to women with CF, prioritize estrogen‑containing options when appropriate, and monitor bone density closely. Prospective studies are needed to clarify causal relationships and guide evidence‑based guidelines.

Original Description

Malinda Wu, pediatric endocrinologist, presented her latest research on the bone health of women with cystic fibrosis during the 2025 North American Cystic Fibrosis conference. Dr. Wu reviews the latest data from the Case 4.CF study, which is a cross-sectional study of self-reported contraceptive use in women with cystic fibrosis. #bonehealth #johnshopkins #cysticfibrosis https://www.hopkinschildrens.org/cf